Clinical Application of OCT in Stent Evaluation

Size: px
Start display at page:

Download "Clinical Application of OCT in Stent Evaluation"

Transcription

1 Imaging & Physiology Summit 2010 in Soul #1. Basics of Image Interpretation: IVUS/VH/OCT Clinical Application of OCT in Stent Evaluation Mitsuyasu Terashima, MD, PhD, FACC

2

3 Stent implantation

4 Stent Apposition

5 Incomplete apposition BX 3.5*33mm After stenting of the mid-lad with inflation pressure at 10 atm Incomplete apposition

6 OCT Image of Implanted stent Just after Deployment Complete stent apposition (CSA) Apposition of stent strut to the vessel wall is evaluated by measuring the distance between the strut surface and adjacent vessel surface. Stent Strut thickness Near infrared light used of strut in OCT cannot penetrate the Dorsal metallic stent strut, so stent Shadowing struts are visualized as linear structures with strong surface reflection and typical dorsal shadowing. Incomplete stent apposition (ISA) Stent Strut > thickness of strut

7 Jornal of Invasive Cardiology 2009;21:

8 A B C D E Fig. 3: Cross sectional optical coherence tomography images of individual stents implanted in the phantom model A: Bx Velocity stent, B: Cypher stent, C: Express2 stent, D: Driver stent, E: Vision stent

9 Frequency (%) A Manufacturer s nominal thickness Frequency (%) B Manufacturer s nominal thickness Strut Thickness m Strut Thickness m 0 Frequency (%) C Manufacturer s nominal thickness Frequency (%) D Manufacturer s nominal thickness Frequency (%) E Manufacturer s nominal thickness Strut Thickness m Strut Thickness m Strut Thickness m Fig. 4: Histograms of measurements of individual stents A: Bx Velocity stent, B: Cypher stent, C: Express2 stent, D: Driver stent, E: Vision stent Jornal of Invasive Cardiology 2009;21:

10 Type of stent Bx- Velocity Table 1. Measured and Manufacturers nominal strut thickness Number Measured Thickness (mm) Table 1 Measured and Manufacturers nominal strut thickness 95% CI (mm) Manufacturer s nominal thickness (mm) to ( inch) Cypher to ( inch + polymer) Express to ( inch) Driver to ( inch) Vision to ( inch) Difference (mm) Measured stent strut thickness in m, expressed as mean SD as compared to manufacturers nominal strut thickness; CI: confidence interval 3 14 Jornal of Invasive Cardiology 2009;21:

11 How to measure? 120µm 140µm 160µm

12 120µm 140µm 160µm

13 Fates of Incomplete Apposition Baseline Incomplete Apposition Healed/Resolved Incomplete Apposition Preserved Incomplete Apposition

14 They concluded that; In Should patients we treat with all SESs. of the ISA incompletely can fail to heal and apposed even struts? complete apposition can be associated Although in-stent with no thrombus neointimal is common hyperplasia. Incomplete findings in DES, stent late apposition stent thrombosis without is a neointimal rare event. hyperplasia was significantly associated Futhermore, with there the is presence no significant of clinical OCT-detected data for relationships thrombus between at follow-up. baseline and ISA may and late constitute stent thrombosis. a potent substrate for late stent Then, thrombosis there any acceptable indication for treatment of ISA?

15 Flap / Dissection IVUS OCT

16 Chronic Vascular Responses to Coronary Stenting by Optical Coherence Tomography

17 Neointimal Coverage of Stent struts

18 IVUS and OCT image of SES at 3-month follow-up OCT provides detailed visualization of the individual stent struts and a thin neointimal layer over DES struts that IVUS can not detect.

19 Classification of Neointimal Coverage ~ Morphology ~

20 Intimal Stent Strut Coverage Type 1 & 2

21 Intimal Stent Strut Coverage Type 3

22 Intimal Stent Strut Coverage Type 4

23 Definition of Neointimal Coverage of Struts Uncovered Struts Covered Struts Type 1 Stent Strut Stent Strut Type 3 NIT Type 2 Dorsal Shadowing Type 4 NIT Ito t, et al, 2006 ACC

24 Intimal Coverage of unapposed Stent Strut

25

26 Classification of Neointimal Coverage of Strut by Kobe University (1) Well apposed with neointima (2) Well apposed without neointima (3) Malapposed with neointima (4) Malapposed without neointima (5) Side branch orifice with neointima (6) Side branch orifice without neointima Malapposition: Incomplete Stent Apposition (ISA) Fig. Images of stent in chronic phase OCT

27 Is the scientific consensus of OCT findings obtained?

28 How about this? No1

29 How about this? No2

30 Comparison of Neointimal Growth between Paclitaxel-Eluting Stent, Sirolimus-Eluting Stent, and Bare-Metal Stent

31 Frequencies of Covered Strut / Stents P < 0.01 ( % ) 100 P < % % % BMS 3M n = 10 PES 3M n = 13 SES 3M n = 13

32 CASE: BMS, SES and PES ~ 4-month f/u ~ Distal

33 CASE: BMS, SES and PES BMS ~ 4-month f/u ~ Cypher Taxus

34 26 head-to-head (n>35,000 ) TAXUS Stent Thrombosis (%) Even with inclusion of the outliers Slope=1.25 n=35, I I I I I I I CYPHER Stent Thrombosis (%) Slope=0.79 TAXUS ST = 1.02 Cypher ST 95% CI (0.79, 1.25) R 2 = Slope= Slope= I-DIABETES I-SMART I-DESIRE TAXI DEScover S.T.E.N.T. SIRTAX MILAN C & T Reward CORPAL REALITY TC-WYRE REAL LONG DES II SORT OUT II BASKET Cervinka Di Lorenzo Han YL Petronio PROSIT Zhang T-SEARCH/RESEARCH DIABETES I, II RESEARCH Long TAXUS Meta / Cypher Meta n=250 n=360 n=200 n=202 n=6,509 n=10,159 n=1,012 n=529 n=2,769 n=652 n=1,353 n=1,558 n=1,676 n=500 n=2,098 n=545 n=70 n=180 n=416 n=100 n=308 n=449 n=1,084 n=160 n=122 n=2,278 Trials excluded in analysis: SOLACI (ST not reported) ARRIVE I / II, e-cypher, TAXUS V and SISR ( differences in protocol definitions).

35 Characteristics of Neointima ~ intensity, pattern ~

36 Usual Neoitima of BMS

37 Common findings in 1 st generation DES SES SES

38 Heterogeneous neointima of 1 st generation DES Layered Mosaic PES SES SES

39 59 y.o. male Pre Post Cypher 2.5*23 Stenting 4M fu

40 Case 2: OCT at 4 months fu

41 Specimen Retrieved by DCA This case will be presented tommorow!

42 Anomalous pattern of Neointima Peri-stent staining Peri-strut ulcer like apperance / Peri-strut halo

43 Neointima following stent implantation have various patterns of morphology or characteristics (intensity, etc). Question? Which patterns are safe (protective for stent thrombosis)? Which patterns are dangerous? Which patterns are within the acceptable range?

44 Summary OCT provides various information and new aspects of implanted stents. Unfortunately, consensus of definition of OCT findings has not been obtained. Therefore, interpretation of the study using OCT requires attention. Lager population study should be required to clarify the relationships between OCT findings and clinical outcomes after achieving consensus standard of OCT findings.

malapposition assessed by OCT

malapposition assessed by OCT Stent t coverage and malapposition assessed by OCT Myeong-Ki Hong, M.D. Ph D Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul,

More information

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT Substudy Carlo Di Mario, MD Peter Barlis, MD Evelyn Regar, MD Peter Juni, MD Patrick

More information

CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus

CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus OPTICAL COHERENCE TOMOGRAPHY (OCT) IVUS and OCT IVUS OCT

More information

Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography.

Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography. Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography. Division of Cardiology, Department of Internal Medicine, Fasculty of Medicine, Kinki University,

More information

Bifurcation Stenting: IVUS and OCT Information

Bifurcation Stenting: IVUS and OCT Information Bifurcation Stenting: IVUS and OCT Information Yoshinobu Murasato MD, PhD (New Yukuhashi Hospital) On behalf of J-REVERSE investigators October 14-15, 2011, Lisbon Proximal stent deformation induced by

More information

Drug eluting stents (DES) have decreased

Drug eluting stents (DES) have decreased JACC: CARDIOVASCULAR IMAGING VOL. 5, NO. 11, 1 1 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36. PUBLISHED BY ELSEVIER INC. http://dx.doi.org/1.116/j.jcmg.1.. BRIEF REPORT OCT-Verified

More information

Optical Coherence Tomography for Intracoronary Imaging

Optical Coherence Tomography for Intracoronary Imaging Optical Coherence Tomography for Intracoronary Imaging Lorenz Räber Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

More information

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research

More information

Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography

Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography B X Chen, F Y Ma, W Luo, J H Ruan, W L Xie, X Z Zhao, S H Sun, X M Guo, F Wang, T Tian, X W Chu

More information

Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography

Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography Journal of Cardiology (2008) 52, 290 295 CASE REPORT Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography Takahiro Sawada (MD),

More information

Usefulness of OCT during coronary intervention

Usefulness of OCT during coronary intervention Usefulness of OCT during coronary intervention Takashi Akasaka, M.D. Department of Cardiovascular Medicine Wakayama, Japan Predictors at 12 Months of Stent Thrombosis and Target Lesion Revascularization

More information

Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD

Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability

More information

OCT; Comparative Imaging Results with IVUS, VH and Angioscopy

OCT; Comparative Imaging Results with IVUS, VH and Angioscopy OCT; Comparative Imaging Results with IVUS, VH and Angioscopy Takashi Akasaka, M.D. Department of Cardiovascular Medicine Wakayama, Japan Comparison among coronary imaging techniques OCT IVUS MRI CAG Angioscopy

More information

Resolute Integrity. Independent Conformability Assessment

Resolute Integrity. Independent Conformability Assessment Resolute Integrity Independent Conformability Assessment Stent Conformability and its Clinical Importance Immediate post-deployment stent geometry determines neointimal thickness independently of arterial

More information

Cover Page. Author: Wang, Ancong Title: Automatic quantification of intravascular optical coherence tomography Issue Date:

Cover Page. Author: Wang, Ancong Title: Automatic quantification of intravascular optical coherence tomography Issue Date: Cover Page The handle http://hdl.handle.net/1887/29690 holds various files of this Leiden University dissertation Author: Wang, Ancong Title: Automatic quantification of intravascular optical coherence

More information

Catch-up Phenomenon: Insights from Pathology

Catch-up Phenomenon: Insights from Pathology Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re

More information

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal? HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic

More information

Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες

Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)

More information

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD Clinical Value of OCT Guidance for Coronary Stenting Giulio Guagliumi, MD 100 % Endovascular Imaging Indications of use 87.5 % 75 % 57.5 % 50 % 45 % 25 % 15 % 0 Lesion morphology Stent optimization Lesion

More information

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents J-S Kim, 1 I-K Jang, 2 J-S Kim, 1 T H Kim, 1 M Takano, 3 T Kume, 4 N

More information

DES in Diabetic Patients

DES in Diabetic Patients DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase

More information

OCT Findings: Lesson from Stable vs Unstable Plaques

OCT Findings: Lesson from Stable vs Unstable Plaques ANGIOPLASTY SUMMIT TCTAP 2010 Imaging Workshop OCT Findings: Lesson from Stable vs Unstable Plaques Giulio Guagliumi MD Ospedali Riuniti di Bergamo, Italy DISCLOSURE OF FINANCIAL INTERESTS Consultant Boston

More information

Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study

Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study DOI 10.1007/s10554-012-0032-6 ORIGINAL PAPER Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study Tuomas Lehtinen

More information

Second Generation Drug Eluting Stents: From Inhibition to Healing

Second Generation Drug Eluting Stents: From Inhibition to Healing Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke

More information

Vessel healings after stenting with different polymers in STEMI patients

Vessel healings after stenting with different polymers in STEMI patients Journal of Geriatric Cardiology (2016) 13: 306 311 2016 JGC All rights reserved; www.jgc301.com Research Article Open Access Vessel healings after stenting with different polymers in STEMI patients Qin-Hua

More information

Acta Cardiol Sin 2018;34: doi: /ACS _34(2) A

Acta Cardiol Sin 2018;34: doi: /ACS _34(2) A Original Article Acta Cardiol Sin 2018;34:124 129 doi: 10.6515/ACS.201803_34(2).20171115A Coronary Artery Disease Vascular Healing Response after Everolimus-Eluting Stent Implantation in Acute Coronary

More information

2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% Nakazawa et al. J Am Coll Cardiol 2011;57:

2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% Nakazawa et al. J Am Coll Cardiol 2011;57: Pathology of In-stent Neoatherosclerosis in BMS and DES 197 BMS, 103 SES, and 106 PES with implant duration >30 days The incidence of neoatherosclerosis was significantly greater in DES (31%) than BMS

More information

SMJ Singapore Medical Journal

SMJ Singapore Medical Journal SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs

More information

Evaluation of stent placement and outcomes with optical coherence tomography

Evaluation of stent placement and outcomes with optical coherence tomography REVIEW Evaluation of stent placement and outcomes with optical coherence tomography Optical coherence tomography (OCT) is an imaging modality based on fiberoptic technology. OCT imaging systems use optical

More information

Next Generation Drug- eluting Stent : Will It Solve the Problem?

Next Generation Drug- eluting Stent : Will It Solve the Problem? Next Generation Drug- eluting Stent : Will It Solve the Problem? Yangsoo Jang, M.D., Ph.D, FACC Severance Cardiovascular Hospital Yonsei University Healthcare System Commercially Available DES An Epidemic

More information

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991

More information

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, 2009 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/09/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.01.012 Incomplete

More information

DES In-stent Restenosis

DES In-stent Restenosis DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms

More information

Drug eluting stents From revolution to evolution. Current limitations

Drug eluting stents From revolution to evolution. Current limitations Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective

More information

Insights in Thrombosis and In-Stent Restenosis

Insights in Thrombosis and In-Stent Restenosis Clinical Value of OCT Insights in Thrombosis and In-Stent Restenosis Fernando Alfonso MD, PhD, FESC Interventional Cardiology. Cardiovascular Institute. Clinico San Carlos University Hospital. Madrid.

More information

Appendix 1: Supplementary tables [posted as supplied by author] Table A. Details of MeSH Search Terms

Appendix 1: Supplementary tables [posted as supplied by author] Table A. Details of MeSH Search Terms Appendix 1: Supplementary tables [posted as supplied by author] Table A. Details of MeSH Search Terms Stent Bare Metal Stent Drug Eluting Stent MeSH terms Randomized controlled trial, clinical trial, Human,

More information

Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI

Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent Masahiko Ochiai MD, FACC, FESC, FSCAI Division of Cardiology and Cardiovascular Surgery Showa University Northern Yokohama Hospital

More information

A Randomized Optical Coherence Tomography Study of Coronary Stent Strut Coverage and Luminal Protrusion With Rapamycin-Eluting Stents

A Randomized Optical Coherence Tomography Study of Coronary Stent Strut Coverage and Luminal Protrusion With Rapamycin-Eluting Stents JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, 2009 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/09/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.01.010 MINI-FOCUS:

More information

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors

More information

eluting Stents The SPIRIT Trials

eluting Stents The SPIRIT Trials Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus

More information

Lessons for technique and stent choice

Lessons for technique and stent choice 8 th European Bifurcation Club 12-13 October 2012 - Barcelona Session: What are the requirements for using a stent in a bifurcation? Lessons for technique and stent choice October 12 th : 16:45 17:50 Goran

More information

Biodegradable Stents An update and work-in

Biodegradable Stents An update and work-in Biodegradable Stents An update and work-in in-progress Department of Cardiology, Hideo Tamai, M.D. Metallic stents... Background induce a varing degree of thrombogenesis eg, subacute thrombosis in complex

More information

Review Article Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement

Review Article Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement ombosis Volume 2012, Article ID 608593, 16 pages doi:10.1155/2012/608593 Review Article Pathologic Etiologies of Late and Very Late Stent ombosis following First-Generation Drug-Eluting Stent Placement

More information

Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study

Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study OrbusNeich Dual Therapy COMBO Stent Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM FACC

More information

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.

More information

Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition

Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J

More information

Bench Insights into Bifurcation Stenting in the DES Era: An Update

Bench Insights into Bifurcation Stenting in the DES Era: An Update Bench Insights into Bifurcation Stenting in the DES Era: An Update John Ormiston, Mark Webster, Peter Ruygrok, Jim Stewart, Douglas Scott, Duncan McNabb, Erin Currie, Monique Panther Mercy Hospital and

More information

Carotid Intravascular Imaging Technique and Indication

Carotid Intravascular Imaging Technique and Indication Nurse and Technician Forum Carotid Intravascular Imaging Technique and Indication Gianmarco de Donato Assistant Professor Vascular and Endovascular Surgery University of Siena - Italy Disclosure Speaker

More information

From a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.

From a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo. Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,

More information

PCI with Polymer-free Stent

PCI with Polymer-free Stent PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution

More information

Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent

Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent implantation. Department of Cardiology, Ehime Prefectural Imabari

More information

Left main coronary artery (LMCA): The proximal segment

Left main coronary artery (LMCA): The proximal segment Anatomy and Pathology of Left main coronary artery G Nakazawa Tokai Univ. Kanagawa, Japan 1 Anatomy Difinition Left main coronary artery (LMCA): The proximal segment RCA AV LAD LM LCX of the left coronary

More information

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.

More information

PCI for Long Coronary Lesion

PCI for Long Coronary Lesion PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2

More information

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.

More information

Non stent based intracoronary drug delivery

Non stent based intracoronary drug delivery Non stent based intracoronary drug delivery Dariusz Dudek Department of Interventional Cardiology Jagiellonian University, Krakow, Poland The European Association of Percutaneous Cardiovascular Interventions

More information

PCI for In-Stent Restenosis. CardioVascular Research Foundation

PCI for In-Stent Restenosis. CardioVascular Research Foundation PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse

More information

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the

More information

BIOFREEDOM: Polymer free Biolimus A9 eluting

BIOFREEDOM: Polymer free Biolimus A9 eluting TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,

More information

INTRODUCTION. Catheterization and Cardiovascular Interventions 82:E871 E878 (2013)

INTRODUCTION. Catheterization and Cardiovascular Interventions 82:E871 E878 (2013) Catheterization and Cardiovascular Interventions 82:E871 E878 (2013) Two-Week Interval Optical Coherence Tomography: Imaging Evidence on Neointimal Coverage Completion After Implantation of the Endeavor

More information

Goal: Optimal Stent Deployment

Goal: Optimal Stent Deployment Ground breaking, Life changing Goal: Optimal Stent Deployment Ground breaking, Life changing Cordis Corporation has no independent knowledge concerning the information contained in these presentations.

More information

ORIGINAL ARTICLE. Methods. Imaging

ORIGINAL ARTICLE. Methods. Imaging Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Imaging Comparison of Neointimal Coverage of Sirolimus-Eluting Stents and Paclitaxel-Eluting

More information

Stents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.

Stents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved. Stents selection and optimal implantation: sizes, design, deployment Stent classification: Mechanism of expansion - Self-expanding - Balloon expandable Design - Mesh structure - Coil - Slotted tube - Ring

More information

Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents

Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2007.12.005 Chronic

More information

European Heart Journal - Cardiovascular Imaging Advance Access published January 4, 2013

European Heart Journal - Cardiovascular Imaging Advance Access published January 4, 2013 European Heart Journal - Cardiovascular Imaging Advance Access published January 4, 2013 European Heart Journal Cardiovascular Imaging doi:10.1093/ehjci/jes299 Natural consequence of post-intervention

More information

IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation

IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation SURE Trial: Restenosis in non-stented lesions Average of the two image slices with the smallest

More information

The Role of Optical Coherence Tomography in Coronary Intervention

The Role of Optical Coherence Tomography in Coronary Intervention review korean j intern med 2012;27:1-12 pissn 1226-3303 eissn 2005-6648 The Role of Optical Coherence Tomography in Coronary Intervention Mitsuyasu Terashima 1, Hideaki Kaneda 2, and Takahiko Suzuki 1

More information

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data

More information

Index. B Bare metal stents (BMS) vs. DES, 172 OCT findings, 170, 172

Index. B Bare metal stents (BMS) vs. DES, 172 OCT findings, 170, 172 Index A Absorbable metal stent (AMS), 189 Absorb BVS, 184 187 Acquired malapposition in DES, stent thrombosis. See also Incomplete stent apposition (ISA) coronary angiography, 155, 156 DAPT therapy, 155

More information

The titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath

The titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath The titanium nitride oxide stent an alternative to DES Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath Advanced Angioplasty 2008 Declaration of interest I have received an honorarium

More information

Intravascular Ultrasound in the Drug-Eluting Stent Era

Intravascular Ultrasound in the Drug-Eluting Stent Era Journal of the American College of Cardiology Vol. 48, No. 3, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.04.068

More information

What Stent to Use? JASVINDAR SINGH MD, FACC

What Stent to Use? JASVINDAR SINGH MD, FACC What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar

More information

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on

More information

Coronary Stent Choice in Patients With Diabetes Mellitus

Coronary Stent Choice in Patients With Diabetes Mellitus Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University

More information

Boston Scientific Corporation Drug-Eluting Stent Program

Boston Scientific Corporation Drug-Eluting Stent Program Boston Scientific Corporation Drug-Eluting Stent Program Copyright 2002 by Scimed Life Systems, Inc. All rights reserved. Program Overview λ λ λ λ λ World Wide Status Restenosis Paclitaxel Polymers Dose

More information

Béla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment

Béla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment Semmelweis University Heart Center Budapest, Hungary Béla MERKELY MD, PhD, DSc, FESC Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment 10th Interventional

More information

DES και θρόμβωση. Dimitrios Alexopoulos

DES και θρόμβωση. Dimitrios Alexopoulos DES και θρόμβωση Dimitrios Alexopoulos 30.10.2008 9 Prospective, Double-Blind, Randomized Trials Freedom From Ischemic TLR 100 RAVEL, SIRIUS, E-SIRIUS, C-SIRIUS (n=1,748) 100 TAXUS I, II, IV, V, VI (n=3,506)

More information

Drug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester

Drug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost

More information

Optical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent

Optical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent Optical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent heart institute, Division of cardiology, Tokyo, Japan Yusuke Watanabe, Ryuta Asano,

More information

Biosensors Lunch Symposium

Biosensors Lunch Symposium Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM

More information

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement

More information

Yukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up

Yukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up Sirolimus Eluting CoCr Coronary Stent System Yukon Chrome PC 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts Yukon Chrome PC DES coating with excellent long-term

More information

Stent thrombosis: How to manage it Dr Philip MacCarthy BSc PhD FRCP Consultant Cardiologist King s College Hospital, London, UK.

Stent thrombosis: How to manage it Dr Philip MacCarthy BSc PhD FRCP Consultant Cardiologist King s College Hospital, London, UK. Stent thrombosis: How to manage it Dr Philip MacCarthy BSc PhD FRCP Consultant Cardiologist King s College Hospital, London, UK. ACI 2011 Weds 26th Jan NO CONFLICT OF INTEREST TO DECLARE A Step-wise practical

More information

Shedding light on stent thrombosis

Shedding light on stent thrombosis Editorial Shedding light on stent thrombosis Tawfiq Choudhury 1,2, Rodrigo Bagur 1,2, Ashlay A. Huitema 1,2, Amir Solomonica 1,2, Shahar Lavi 1,2 1 Department of Medicine, Western University, London, ON,

More information

BioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program

BioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program BioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program T. Santoso Univ. of Indonesia Medical School Medistra Hospital Jakarta, Indonesia Biodegradable Abluminally Coated

More information

The 3 top Messages from technique Specific problems Solving

The 3 top Messages from technique Specific problems Solving The 3 top Messages from technique Specific problems Solving Alaide Chieffo Interventional Cardiology Unit San Raffaele Hospital Milan - Italy PROBLEMS DURING PROVISIONAL: SB PROTECTION AND RESCUE Francesco

More information

Pathology of Cardiovascular Interventions. Body and Disease 2011

Pathology of Cardiovascular Interventions. Body and Disease 2011 Pathology of Cardiovascular Interventions Body and Disease 2011 Coronary Artery Atherosclerosis Intervention Goals: Acute Coronary Syndromes: Treat plaque rupture and thrombosis Significant Disease: Prevent

More information

For Personal Use. Copyright HMP 2013

For Personal Use. Copyright HMP 2013 Original Contribution Predictors of Stent Strut Malapposition in Calcified Vessels Using Frequency-Domain Optical Coherence Tomography Alistair C. Lindsay, MD, PhD 1, Manuel Paulo, MD 1, Kilickesmez Kadriye,

More information

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center 2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular

More information

Can IVUS Define Plaque Features that Impact Patient Care?

Can IVUS Define Plaque Features that Impact Patient Care? Can IVUS Define Plaque Features that Impact Patient Care? A Pichard L Satler, K Kent, R Waksman, W Suddath, N Bernardo, N Weissman, M Angelo, D Harrington, J Lindsay, J Panza. Washington Hospital Center

More information

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research The Cardiovascular

More information

Comparison of Optical Coherence Tomographic Assessment between First- and Second-Generation Drug-Eluting Stents

Comparison of Optical Coherence Tomographic Assessment between First- and Second-Generation Drug-Eluting Stents Original Article http://dx.doi.org/10.3349/ymj.2012.53.3.524 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 53(3):524-529, 2012 Comparison of Optical Coherence Tomographic Assessment between First- and

More information

Drug eluting balloons in CAD

Drug eluting balloons in CAD Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features

More information

FOR IMMEDIATE RELEASE

FOR IMMEDIATE RELEASE FOR IMMEDIATE RELEASE Global Media Contacts: David Schull or Ian Stone Russo Partners +1 212-845-4271 +1 619-528-2220 david.schull@russopartnersllc.com ian.stone@russopartnersllc.com David Kujawa OrbusNeich

More information

Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank

Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular

More information

LCX. President / Director of Cardiology / New Tokyo Hospital

LCX. President / Director of Cardiology / New Tokyo Hospital LCX President / Director of Cardiology / New Tokyo Hospital Professor of Department of Advanced Cardiovascular Medicine: Kumamoto University Consultant / National Cardiovascular Center / Osaka Sunao Nakamura

More information

Optical Coherence Tomography

Optical Coherence Tomography Optical Coherence Tomography Disclosure Information Demetrius Lopes MD The following relationships exist related to this presentation: University Grant/Research Support: Rush University Industry Grant

More information

World Congress of Cardiology PARIS: August 27-31, ESC Andreas Gruentzig lecture on Interventional Cardiology

World Congress of Cardiology PARIS: August 27-31, ESC Andreas Gruentzig lecture on Interventional Cardiology World Congress of Cardiology PARIS: August 27-31, 2011 ESC Andreas Gruentzig lecture on Interventional Cardiology Stent optimization and dual antiplatelet therapy: what has been done and what needs to

More information

as a Mechanism of Stent Failure

as a Mechanism of Stent Failure In-Stent t Neoatherosclerosis e osc e os s as a Mechanism of Stent Failure Soo-Jin Kang MD., PhD. University of Ulsan College of Medicine, Heart Institute Asan Medical Center, Seoul, Korea Disclosure I

More information

DESolve NX Trial Clinical and Imaging Results

DESolve NX Trial Clinical and Imaging Results DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or

More information